It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.

[37] Real-world test-negative analysis in Bahrain (based on 14 days post 2nd dose) indicated a vaccine effectiveness of 90% (95% CI, 88–91%) for adults aged 18–59, and 91% (87–94%) for those 60 year old or older.

[41] On 22 July, Peru's National Institute of Health reported the vaccine reduced deaths by 94% after analyzing data from 361,000 people.

[42] On 13 August, a study with 400,000 health workers in Peru from February to June 2021, during a wave mostly caused by the Lambda and Gamma variants, found a vaccine effectiveness of 50% (49–52%) against infection and 94% (91–96%) against death after two doses.

[43][44] On 24 August, preliminary results from a non-randomized study of one million people in Bahrain, of whom 569,054 received the BIBP vaccine, found that the vaccine continued to reduce infection, hospitalization, and death when the Delta variant became dominant, though not as effectively as Pfizer–BioNTech, Oxford–AstraZeneca and Sputnik V.[45] In December 2020, UAE's Ministry of Health and Prevention previously announced interim analysis showing the vaccine to have a 86% efficacy against COVID-19 infection and nearly 100% efficacy in preventing moderate and severe cases.

[47] On 7 May 2021, the World Health Organization reported a vaccine efficacy of 79% (95% CI, 66–88%) against symptomatic disease and 79% (26–94%) against hospitalization.

From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact.

[30] In March 2021, Sinopharm and Abu Dhabi G42 announced plans to produce up to 200 million doses annually in the UAE at a new plant to become operational in 2021.

[56] In March 2021, Serbia announced plans to produce 24 million doses of the BIBP vaccine annually starting in October.

[58] In July 2021, Morocco's Société Thérapeutique Marocaine announced it would produce 5 million doses a month.

[59] In November 2021, Sinopharm announced that it will build a sterile bottling plant in Singapore to enhance the distribution of the vaccine.

[17] In July 2020, Sinopharm began trials with 31,000 volunteers in the UAE in collaboration with G42 Healthcare, an Abu Dhabi-based company.

[62] In June 2021, Sinopharm began Phase III trials for children and adolescents aged 3–17 with 1,800 volunteers.

[76] On 30 December 2020, China's National Medical Products Administration approved the BIBP vaccine for general use.

[109] In January 2021, Laos began vaccinating healthcare workers in Vientiane[110] and received another 300,000 doses in early February.

[111] In April 2021, Lebanon received a donation of 90,000 doses from China[112][113] after granting emergency use authorization on 2 March.

[118] On 10 March, Governor of Ulaanbaatar D. Sumiyabazar and Deputy Prime Minister S. Amarsaikhan received the first doses.

[125] In April 2021, Philippines president Rodrigo Duterte received the vaccine after the food and drug regulator approved compassionate use of 10,000 doses for his security team.

[131] On 14 September 2020, the United Arab Emirates approved the vaccine for front-line workers following interim Phase III trials.

[47] In March, a small number of people who have reduced immunity against diseases, chronic illnesses, or belong to high-risk groups have been given a third booster dose.

[154][155] In February, Mozambique received a donation of 200,000 doses from China[156] and planned to start vaccinations on 8 March.

[157] In March, Namibia received a donation of 100,000 doses from China and announced the start of vaccinations in the Khomas and Erongo regions.

[170][171] In March, Republic of the Congo received 100,000 Chinese-donated doses with vaccinations prioritizing the medically vulnerable and those over 50.

[178] In January, Hungary became first member of the European Union to approve the BIBP vaccine, signing a deal for 5 million doses.

[184] In April, North Macedonia received the first 200,000 of 800,000 doses which arrived from Serbia[185] which was used in the vaccination campaign starting 4 May.

[189][190] In March, Mexico announced it would order 12 million doses of the BIBP vaccine pending approval by its health regulator,[191] which was granted in August.

[193] In April, Barbados announced it would receive 30,000 doses of Chinese donated the BIBP vaccine, according to Prime Minister Mia Mottley.

They were vaccinated with extra doses that were brought in for the Phase III trials being conducted by Cayetano Heredia University in Lima with 12,000 volunteers.

[207][72] In May 2021, Philippine President Rodrigo Duterte apologized for taking the BIBP vaccine which was not approved at the time.

In response, Duterte said China should in the future only send CoronaVac, a separate vaccine which was approved in the Philippines at the time.